Delcath Systemsincis A Specialty Pharmaceutical And Medical Device Company Based In Queensburynew Yorkfounded In 1988 And Publicly Traded On Nasdaq Under The Ticker Dcthdelcath Focuses On Interventional Oncologyparticularly For Primary And Metastatic Liver Cancersthe Company Aims To Improve Patient Outcomes Through Innovative Technologies That Deliver Targeted Treatments While Minimizing Harm To Healthy Tissue Delcath S Flagship Product Is The Percutaneous Hepatic Perfusionphpsystemwhich Allows For The Direct Administration Of High Dose Chemotherapy To The Liverthe Company Also Offers The Generation Two Chemosat Systemfeaturing Enhanced Hemofiltration Efficiencydelcath Is Actively Involved In Clinical Trials For Its Php Systemcollaborating With The National Cancer Institute And Receiving Fda Designations For Its Treatment Protocolswith A Strong Intellectual Property Portfolio Of 28 Patentsdelcath Is Recognized For Its Contributions To Oncology And Is Committed To Providing New Treatment Options For Patients With Liver Cancers
